US Plasma Protein Therapeutics Market Segmentation By Product Type, By Application & by Region with Forecast 2017-2030

United States Plasma Protein Therapeutics Market Overview

Approximately 18,000 people are living with hemophilia in the United States, among which about 80% of people with hemophilia have hemophilia A. However, about 20% of people have hemophilia B (factor IX deficiency). Many of the technological advances in hemophilia treatment have come with high financial price tags. The life-long management of hemophilia places a large financial burden upon individuals and families. In fact, the average annual cost of clotting factor products can range from USD 50,000 to USD 100,000. Complications such as inhibitors, orthopedic surgery, hepatitis, and HIV disease can cause the costs to be even higher. Every year, more than 22 million liters of plasma is utilized to manufacture life-saving medicines to treat more than one million people around the world. Baxter works closely with the Plasma Protein Therapeutics Association, or PPTA, to raise awareness of the importance of plasma donation to support a growing, global need for plasma-derived therapies.

United States plasma protein therapeutics market is estimated to be at USD 19.78 billion in 2017 and is poised to grow at a CAGR of 8.45% through the forecast period 2017-2030. Increasing geriatric population, increasing new patient registration for hemophilia treatment, increased penetration of plasma derived products, rise in the number of clinical indications for immunoglobulin and investments in novel researches are boosting prospects for the market. Rare disorder like treatment of hereditary angioedema (HAE) has become possible due to the plasma protein therapeutics. However, stringent regulations and lack of proper reimbursement policies could hamper the plasma protein therapeutics market’s trajectory.

United States Plasma Protein Therapeutics Market Segmentation

By Product Type

• Albumin
• Hyperimmunes (IM & IV)
• Factor VIII (Plasma Derived)
• Factor IX (Plasma Derived)
• Polyvalent IVIG/SCIG

Polyvalent IVIG/SCIG accounts for 45% of the United States plasma proteins therapeutics market in 2017 that may vary significantly by regional population. Albumin and plasma-derived factor VIII (pdFVIII) each have a smaller share of the market (11-16% each) again with wide regional variations.

By Application

• Hemophilia
• Primary Immunodeficiency Disorder
• Idiopathic Thrombocytopenic Purpura
• Secondary Immunodeficiency (CLL, multiple myeloma, congenital aids)
• Hereditary Angioedema

Plasma protein therapeutics is increasingly used in the treatment of primary immunodeficiency disorder (PID) and is likely to exhibit a CAGR of 7.34% between 2017 and 2030. Trailed by the increasing incidence of secondary immunodeficiency disorders like diabetes, myeloma, HIV infection, and under-nutrition, applications of plasma protein therapeutics is likely to increase across the treatment of prolonged illnesses.

Covered In This United States Plasma Protein Therapeutics Market Report                                                                                                                  

The report covers the present ground scenario and the future growth prospects of the facility management market for 2017-2030 along with the market players’ analysis. We calculated the market size and revenue share on the basis of revenue generated from major players worldwide. Plasma Protein Therapeutics market is forecasted on the basis of revenue analysis, product benchmarking and strategic developments of key market players.

United States Plasma Protein Therapeutics Market Outlook 2017-2030, has been prepared based on an in-depth market analysis from industry experts. The report covers the competitive landscape and current position of major players in the plasma protein therapeutics market space. The report also includes porter’s five force model, SWOT analysis, company profiling, business strategies of market players and their business models. “United States Plasma Protein Therapeutics Market Report” also recognizes value chain analysis to understand the cost differentiation, pricing models to provide competitive advantage to the existing and new entry players.

Key Market Players

Our United States Plasma Protein Therapeutics Market Report comprises of the following companies as the key players:  

• Baxter
• CSL
• Grifols
• Octapharma
• Bayer
• Biotest
• Kedrion
• CBOP
• RAAS
• Hualan Bio
• Tiantan Bio
• Shuanglin Bio
• BOYA.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

For a full detailed overview, send us the sample request.

Key questions answered in this United States Plasma Protein Therapeutics Market Report

• What is the total market size by 2030 and what would be the expected growth rate of market?
• What is the total revenue per segment and region in 2016-17 and what would be the expected revenue per segment and region over the forecast period?
• What are the key market trends?
• What are the factors which are driving this market?
• What are the major barriers to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities for the existing and entry level players?
• What are the recent developments and business strategy of the key players?

Reasons to buy this market study

• Facilitate decision-making based on strong historic and forecast data for Plasma Protein Therapeutics Market
• Develop strategies based on the latest regulatory framework
• Position yourself to gain the maximum advantage of the Healthcare industry’s growth potential
• Identify key partners and business development avenues across the globe
• Respond to your competitors’ business structure, strategy and prospects
• Strategically analyze micro-markets with respect to individual growth trends, future prospects, and their contribution to the market
• Analyze competitive developments such as expansions, investments, mergers & acquisitions, new product developments, and research & developments in the Plasma Protein Therapeutics market
• Analyze the opportunities in the market for stakeholders and draw a competitive landscape for market leaders
• To strategically profile key players and comprehensively analyze their market shares and core competencies